Christl A. Donnelly

2 months ago | nature.com | Serina Chang |Samantha Vanderslott |Elizaveta Semenova |Oliver Watson |Abhishek Dasgupta |Samuel V. Scarpino | +14 more

AbstractInfectious disease threats to individual and public health are numerous, varied and frequently unexpected. Artificial intelligence (AI) and related technologies, which are already supporting human decision making in economics, medicine and social science, have the potential to transform the scope and power of infectious disease epidemiology.

Oct 31, 2023 | nature.com | Younjung Kim |Guillaume Fournié |Raphaëlle Métras |Christl A. Donnelly |Dirk Pfeiffer

Recent highly pathogenic avian influenza A(H5N1) outbreaks in two Korean cat shelters highlight the need to enhance surveillance for cross-species viral transmission into animal populations kept by humans for non-agricultural or non-conventional livestock farming purposes from a One Health perspective. Cross-species viral transmission refers to the infection of a new host species by a virus, commonly referred to as ‘spillover'1,2.

Oct 24, 2023 | nature.com | Christina J Atchison |Bethan Davies |Emily Cooper |Christl A. Donnelly |Marc Chadeau-Hyam |Graham Cooke | +1 more

AbstractThe COVID-19 pandemic is having a lasting impact on health and well-being. We compare current self-reported health, quality of life and symptom profiles for people with ongoing symptoms following COVID-19 to those who have never tested positive for SARS-CoV-2 infection and those who have recovered from COVID-19. Overall, 276,840/800,000 (34·6%) of invited participants took part.

Aug 16, 2023 | nature.com | Bethan Davies |Christina J Atchison |Wendy Barclay |Deborah Ashby |Ara Darzi |Graham Cooke | +3 more

AbstractThe value of SARS-CoV-2 lateral flow immunoassay (LFIA) tests for estimating individual disease risk is unclear. The REACT-2 study in England, UK, obtained self-administered SARS-CoV-2 LFIA test results from 361,801 adults in January-May 2021. Here, we link to routine data on subsequent hospitalisation (to September 2021), and death (to December 2021).

Jun 19, 2023 | adc.bmj.com | Christina J Atchison |Matthew Whitaker |Christl A. Donnelly |Marc Chadeau-Hyam

Data analysisWe estimated the prevalence of persistent symptoms at 3 months postsymptom onset in individuals with a history of COVID-19. We included all self-reported prior COVID-19 episodes including test confirmed and suspected but not confirmed. We only included those who reported onset of COVID-19 ≥3 months prior to the date of the survey and for whom we had complete data.